ADHD Med Trials Often Miss the Mark

 ADHD in the News 2025-01-16


Clinical relevance: Persistent Adderall shortages and rising diagnoses highlight the mismatch between randomized controlled trials and real-world ADHD treatment. A Swedish study revealed that more than 53 percent of nearly 190,000 ADHD patients would not qualify for traditional RCTs. Ineligible patients faced significantly higher risks of adverse outcomes, including psychiatric hospitalizations and specialist care for mental health and substance use issues. RCTs often exclude patients with comorbid conditions, creating a gap between trial findings and real-world treatment needs.